- Home
- RXRX vs ATRC Comparison
RXRX vs ATRC Comparison
Compare RXRX & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- ATRC
- Stock Information
- Founded
- RXRX 2013
- ATRC 2000
- Country
- RXRX United States
- ATRC United States
- Employees
- RXRX N/A
- ATRC N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- ATRC Medical/Dental Instruments
- Sector
- RXRX Health Care
- ATRC Health Care
- Exchange
- RXRX Nasdaq
- ATRC Nasdaq
- Market Cap
- RXRX 2.1B
- ATRC 1.7B
- IPO Year
- RXRX 2021
- ATRC 2005
- Fundamental
- Price
- RXRX $5.91
- ATRC $36.75
- Analyst Decision
- RXRX Buy
- ATRC Strong Buy
- Analyst Count
- RXRX 4
- ATRC 10
- Target Price
- RXRX $7.25
- ATRC $49.60
- AVG Volume (30 Days)
- RXRX 39.6M
- ATRC 371.4K
- Earning Date
- RXRX 11-05-2025
- ATRC 10-29-2025
- Dividend Yield
- RXRX N/A
- ATRC N/A
- EPS Growth
- RXRX N/A
- ATRC N/A
- EPS
- RXRX N/A
- ATRC N/A
- Revenue
- RXRX $64,596,000.00
- ATRC $499,946,000.00
- Revenue This Year
- RXRX $24.17
- ATRC $16.32
- Revenue Next Year
- RXRX $20.98
- ATRC $12.37
- P/E Ratio
- RXRX N/A
- ATRC N/A
- Revenue Growth
- RXRX 30.14
- ATRC 16.28
- 52 Week Low
- RXRX $3.79
- ATRC $25.57
- 52 Week High
- RXRX $12.36
- ATRC $43.11
- Technical
- Relative Strength Index (RSI)
- RXRX 62.64
- ATRC 55.28
- Support Level
- RXRX $5.11
- ATRC $33.74
- Resistance Level
- RXRX $6.30
- ATRC $35.76
- Average True Range (ATR)
- RXRX 0.39
- ATRC 1.19
- MACD
- RXRX 0.12
- ATRC -0.00
- Stochastic Oscillator
- RXRX 70.23
- ATRC 60.55
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.